Navigation Links
Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor
Date:5/8/2008

combination with other approved cancer drugs. ENMD-2076 is unique-in-class because it not only inhibits Aurora A selectively, it also inhibits a cluster of kinases that are important for tumor growth, particularly growth factor receptors critical to angiogenesis. ENMD-2076 has potent antitumor activity in multiple preclinical models, including both solid tumors and hematological cancers."

James S. Burns, EntreMed President & Chief Executive Officer commented, "Further development of ENMD-2076 is consistent with both our focus on investing behind oncology drug candidates with strong single-agent activity and our continuing interest in kinase inhibitors. In keeping with our 2008 goals of cash preservation and rigorous resource management, we intend to pay the $2 million Phase 1 milestone to Miikana shareholders in shares of EntreMed common stock. Our goals for this program over the next twelve months are to complete the clinical trial in solid tumor patients, initiate a clinical trial in patients with hematological cancers, and secure a pharmaceutical partner to help accelerate the development of ENMD-2076."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at '/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... have developed a unique nanoscale device that for ... The discovery could have major implications for creating ... and communication. , The research paper by University ... Mo Li and his graduate student Huan Li ... the October issue of Nature Nanotechnology . ...
(Date:9/22/2014)... Rhinebeck, NY (PRWEB) September 22, 2014 ... commitment helping those in pain end their suffering, restoring ... sustainable healthcare model. This is only possible because of ... relief and healing cream technology a reality. , ... in Rhinebeck, NY, by Lou Paradise (president, chief of ...
(Date:9/22/2014)... WORCESTER, Mass. and TORONTO ... Biotechnology Corporation ( www.generex.com ) (OTCBB:GNBT) today announced ... University Health Network (UHN) pursuant to which UHN,s ... spearhead the Company,s buccal insulin refinement project.  The ... insulin bioavailability of Generex Oral-lyn™, the Company,s proprietary ...
(Date:9/22/2014)... September 22, 2014 METTLER TOLEDO ... and pallet measuring device CNS110 ScanTape™ . ... data entry, offering greater ease and accuracy for ... result can significantly enhance productivity—an important benefit for ... processing volume equals profits. , Usable at ...
Breaking Biology Technology:Engineers show light can play seesaw at the nanoscale 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4ScanTape™ Handheld Dimensioner Increases Processing Volume 2
... Conversations about Plant Biotechnology Video Available Online , ... ... about Plant Biotechnology Web site expanded its video offering to include ... "What,s for Lunch?" -- addresses consumer concerns about food choices and ...
... Aug. 11 BioSpecifics,Technologies Corp. (OTC Bulletin Board: BSTC.OB), ... its financial results for the second quarter ended June ... of $801,337 for the quarter ended June,30, 2008, or ... net loss of,$478,000, or 9 cents per diluted common ...
... "Rewards and recognition are,driven from an internal program ... and internal," said one participant in a,member-driven research ... Structuring and managing the program to maintain ... large organizations.,One-third of study respondents cite the need ...
Cached Biology Technology:Is GMO Food and Organic Food an Either/Or Proposition? 2Is GMO Food and Organic Food an Either/Or Proposition? 3BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results 2BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results 3BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results 4BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results 5BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results 6Consistency, Flexibility Key in Improving Rewards & Recognition Programs 2
(Date:9/21/2014)... mussels and barnacles secrete very sticky proteins that help ... Inspired by these natural adhesives, a team of MIT ... to repair ships or help heal wounds and surgical ... MIT researchers engineered bacteria to produce a hybrid material ... a bacterial protein found in biofilms slimy layers ...
(Date:9/19/2014)... biology professor will study the unique bioelectric signaling system ... benefit people,s health. The OU researcher is working ... to produce the signals used to map the world ... a rate of 500-600 discharges a second throughout their ... fish are extreme, but necessary for survival. , "There ...
(Date:9/19/2014)... Sept. 19, 2014 Nxt-ID, Inc. (Nasdaq: NXTD ... focused on the growing m-commerce market, updates the "Wocket in Your ... the lightweight and light middleweight weight classes, Vinny Pazienza ... announced that Game of Thrones actor Ciaran Hinds ... Children star Katey Sagal have been cast in ...
Breaking Biology News(10 mins):Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3
... concerns about jobs in the headlines around the world, this ... C&EN ) presents a 3-part cover story on the jobs ... 96% of all manufactured goods, with the chemical industry in ... is the weekly newsmagazine of the American Chemical Society, ...
... of Philadelphia and BGI, the world,s largest genomics ... BGI@CHOP, to conduct large-scale human genome sequencing and ... Genome Center at Children,s Hospital. The partnership will ... and common pediatric diseases using next-generation sequencing. The ...
... innovation hub poised to integrate and fast track research, ... at University Health Network (UHN) and the University of ... VP, Research at UHN says: "Techna is a fresh ... holds the key to understanding many diseases and Techna ...
Cached Biology News:Children's Hospital of Philadelphia and BGI announce partnership and new Joint Genome Center 2UHN, University of Toronto launch Techna innovation hub to get health technologies to patients faster 2